Cargando…
A Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities
Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 20% to 30% of breast cancers and various other types of cancers, which plays a vital role in the cancer progression. Monoclonal antibodies targeting Her2 are now used in the clinic to treat Her2 overexpression cancer p...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852409/ https://www.ncbi.nlm.nih.gov/pubmed/29455083 http://dx.doi.org/10.1016/j.tranon.2018.01.024 |